Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling

References

• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Bladder Cancer. National Comprehensive Cancer Network; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed February 16, 2023.
   Google Scholar
• Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244–258. doi:10.1016/j.annonc.2021.11.012
   PubMed Web of Science ®Google Scholar
• Bloudek L, Hepp Z, McKay C, et al. Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC). J Clin Oncol. 2022;40(suppl 6):570. doi:10.1200/JCO.2022.40.6_suppl.570
   Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN bladder 100 trial. J Clin Oncol. 2022;40(suppl 6):487. doi:10.1200/JCO.2022.40.6_suppl.487
   Google Scholar
• Food and Drug Administration. Successes and Opportunities in Modeling and Simulation for FDA. Food and Drug Administration; 2022.
   Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi:10.1016/j.ejca.2022.09.031
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Montironi R, et al. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers. 2020;12(6):1449. doi:10.3390/cancers12061449
   PubMed Web of Science ®Google Scholar
• Schwartz N, DeBusk K, Bloudek L, Migliaccio-Walle K, Bloudek B. Estimation of the prevalence of HER2+ metastatic breast cancer in the United States. J Manag Care Pharm. 2021;27(suppl 10b):S1–S119.
   Google Scholar
• Bloudek B, Wirtz H, Hepp Z, et al. Oncology simulation model: a comprehensive and innovative approach to estimate and project prevalence and survival in oncology. Clin Epidemiol. 2022;14:1375–1386. doi:10.2147/CLEP.S377093
   PubMed Web of Science ®Google Scholar
• Phillips T, Migliaccio-Walle K, Yu KS, et al. An oncology simulation model to estimate 10-year progression-free survival and stem cell transplantation for frontline, stage III or IV classical Hodgkin lymphoma based on the 5-year update of the ECHELON-1 trial: a United States perspective. Blood. 2021;138(suppl 1):2440. doi:10.1182/blood-2021-147308
   Google Scholar
• Phillips TJ, Liu N, Bloudek B, Migliaccio-Walle K, Reynolds J, Burke JM. 10-year impact on productivity costs associated with mortality in stage III or IV classical Hodgkin lymphoma based on the overall survival update of the ECHELON-1 trial: application of an oncology simulation model in the United States. Blood. 2022;140(suppl 1):10791–10792. doi:10.1182/blood-2022-162573
   Google Scholar
• Burke JM, Yu KS, Mordi U, et al. An oncology simulation model to estimate 10-year progression-free survival and overall survival based on the 5-year update from the ECHELON-2 trial in frontline patients with peripheral T-cell lymphoma: a United States perspective. Blood. 2021;138(suppl 1):2466. doi:10.1182/blood-2021-148004
   Google Scholar
• Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931–945. doi:10.1016/S1470-2045(21)00152-2
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. doi:10.1056/NEJMoa2002788
   PubMed Web of Science ®Google Scholar
• Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547–1557. doi:10.1016/S0140-6736(20)30230-0
   PubMed Web of Science ®Google Scholar
• Morgans A, Powles T, Shih V, et al. C27. Real-World Avelumab Maintenance Eligibility and Treatment Patterns in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma. San Antonio, Texas, United States: JMCP; 2023.
   Google Scholar
• Powles T, van der Heijden M, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574–1588. doi:10.1016/S1470-2045(20)30541-6
   PubMed Web of Science ®Google Scholar
• Galsky MD, Sonpavde GP, Bloudek B, et al. Simulating the Impact of First-Line Treatment Choice on Survival Among Patients with Locally Advanced/Metastatic Urothelial Carcinoma Considered Cisplatin Ineligible. Boston, United States: ISPOR; 2023.
   Google Scholar
• García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017;18(5):672–681a. doi:10.1016/S1470-2045(17)30242-5
   PubMed Web of Science ®Google Scholar
• Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind Phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020;38(16):1797–1806. doi:10.1200/JCO.19.03091
   PubMed Web of Science ®Google Scholar
• Bloudek L, Campbell D, Pandey R, Migliaccio-Walle K, Bloudek B, Devine B. MSR33 application and feasibility of indirect treatment comparison of switch maintenance and non-maintenance oncology regimens to inform HTA decision-making. Value Health. 2022;25(12):S356. doi:10.1016/j.jval.2022.09.1765
   Web of Science ®Google Scholar